Penumbra Stock Forecast, Price & News

+2.36 (+0.82 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume129,760 shs
Average Volume307,956 shs
Market Capitalization$10.65 billion
P/E Ratio677.30
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Penumbra logo

About Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.38 out of 5 stars

Medical Sector

182nd out of 1,352 stocks

Surgical & Medical Instruments Industry

21st out of 123 stocks

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Penumbra (NYSE:PEN) Frequently Asked Questions

Is Penumbra a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Penumbra stock.
View analyst ratings for Penumbra
or view top-rated stocks.

What stocks does MarketBeat like better than Penumbra?

Wall Street analysts have given Penumbra a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Penumbra wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Penumbra

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) released its earnings results on Monday, August, 9th. The company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.02. The firm earned $184.26 million during the quarter, compared to analyst estimates of $170.77 million. Penumbra had a trailing twelve-month return on equity of 5.52% and a net margin of 2.37%. The firm's quarterly revenue was up 75.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) earnings per share.
View Penumbra's earnings history

How has Penumbra's stock price been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PEN shares have increased by 64.7% and is now trading at $291.24.
View which stocks have been most impacted by COVID-19

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $720 million-$730 million, compared to the consensus revenue estimate of $702.42 million.

What price target have analysts set for PEN?

6 brokers have issued twelve-month price targets for Penumbra's stock. Their forecasts range from $270.00 to $350.00. On average, they anticipate Penumbra's stock price to reach $324.86 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Penumbra
or view top-rated stocks among Wall Street analysts.

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Adam Elsesser, Chairman, President & Chief Executive Officer
  • Ben Sorci, Executive Vice President-Operations
  • Maggie S. Yuen, Chief Financial Officer
  • Michaella Corso, Vice President-Clinical Affairs
  • Pankaj Tiwari, Vice President-Information Technology

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra CEO Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among Penumbra's employees.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), The Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.96%), Vanguard Group Inc. (8.87%), BlackRock Inc. (8.75%), Baillie Gifford & Co. (3.67%), Price T Rowe Associates Inc. MD (3.43%) and Clearbridge Investments LLC (2.81%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder.
View institutional ownership trends for Penumbra

Which institutional investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Morgan Stanley, William Blair Investment Management LLC, Franklin Resources Inc., Marshall Wace LLP, Marshall Wace LLP, and Price T Rowe Associates Inc. MD. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, and Thomas Wilder.
View insider buying and selling activity for Penumbra
or view top insider-selling stocks.

Which institutional investors are buying Penumbra stock?

PEN stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Amundi, State Street Corp, First Trust Advisors LP, Neuberger Berman Group LLC, PFM Health Sciences LP, Baillie Gifford & Co., and Balyasny Asset Management LLC.
View insider buying and selling activity for Penumbra
or or view top insider-buying stocks.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $291.24.

How much money does Penumbra make?

Penumbra has a market capitalization of $10.65 billion and generates $560.41 million in revenue each year. The company earns $-15,700,000.00 in net income (profit) each year or $0.11 on an earnings per share basis.

How many employees does Penumbra have?

Penumbra employs 3,300 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

Where are Penumbra's headquarters?

Penumbra is headquartered at One Penumbra Place, Alameda CA, 94502.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at (510) 748-3200 or via email at [email protected]

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.